Cynosure (NASDAQ: CYNO) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Institutional & Insider Ownership
11.6% of Pulse Biosciences shares are owned by institutional investors. 2.9% of Cynosure shares are owned by company insiders. Comparatively, 6.7% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Cynosure and Pulse Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure currently has a consensus target price of $66.00, indicating a potential upside of Infinity. Given Cynosure’s higher probable upside, research analysts clearly believe Cynosure is more favorable than Pulse Biosciences.
Valuation & Earnings
This table compares Cynosure and Pulse Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pulse Biosciences||N/A||N/A||-$9.51 million||($1.39)||-13.31|
Pulse Biosciences is trading at a lower price-to-earnings ratio than Cynosure, indicating that it is currently the more affordable of the two stocks.
This table compares Cynosure and Pulse Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cynosure beats Pulse Biosciences on 6 of the 8 factors compared between the two stocks.
Cynosure Company Profile
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Receive News & Ratings for Cynosure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure and related companies with MarketBeat.com's FREE daily email newsletter.